JPWO2020160441A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020160441A5
JPWO2020160441A5 JP2021544728A JP2021544728A JPWO2020160441A5 JP WO2020160441 A5 JPWO2020160441 A5 JP WO2020160441A5 JP 2021544728 A JP2021544728 A JP 2021544728A JP 2021544728 A JP2021544728 A JP 2021544728A JP WO2020160441 A5 JPWO2020160441 A5 JP WO2020160441A5
Authority
JP
Japan
Prior art keywords
trem2
optionally
cells
acid sequence
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021544728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523123A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/016163 external-priority patent/WO2020160441A1/fr
Publication of JP2022523123A publication Critical patent/JP2022523123A/ja
Publication of JPWO2020160441A5 publication Critical patent/JPWO2020160441A5/ja
Pending legal-status Critical Current

Links

JP2021544728A 2019-02-01 2020-01-31 神経認知障害を処置するための組成物及び方法 Pending JP2022523123A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962800056P 2019-02-01 2019-02-01
US62/800,056 2019-02-01
PCT/US2020/016163 WO2020160441A1 (fr) 2019-02-01 2020-01-31 Compositions et méthodes pour le traitement de troubles neurocognitifs

Publications (2)

Publication Number Publication Date
JP2022523123A JP2022523123A (ja) 2022-04-21
JPWO2020160441A5 true JPWO2020160441A5 (fr) 2023-04-25

Family

ID=71841290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544728A Pending JP2022523123A (ja) 2019-02-01 2020-01-31 神経認知障害を処置するための組成物及び方法

Country Status (7)

Country Link
US (1) US20220133850A1 (fr)
EP (1) EP3917623A4 (fr)
JP (1) JP2022523123A (fr)
CA (1) CA3127804A1 (fr)
IL (1) IL285268A (fr)
MA (1) MA54873A (fr)
WO (1) WO2020160441A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2023196470A1 (fr) * 2022-04-07 2023-10-12 The Regents Of The University Of California Méthodes de traitement de la maladie d'alzheimer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074942A1 (fr) * 2012-11-08 2014-05-15 Illumina, Inc. Variants de risque de développer la maladie d'alzheimer
WO2017147509A1 (fr) * 2016-02-25 2017-08-31 Marco Colonna Compositions comprenant de la trem2 et leurs procédés d'utilisation
WO2018015573A2 (fr) * 2016-07-22 2018-01-25 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Modulateurs du clivage de trem2 et leurs utilisations
US20200207830A1 (en) * 2017-07-27 2020-07-02 Novartis Ag Trem2 mutants resistant to sheddase cleavage

Similar Documents

Publication Publication Date Title
US11965174B2 (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
US20190127424A1 (en) Capsid-modified raav vector compositions and methods therefor
Iida et al. Systemic delivery of tyrosine‐mutant AAV vectors results in robust transduction of neurons in adult mice
JP2022508182A (ja) 組換えウイルスベクター及びそれの産生のための核酸
EP2500434A1 (fr) Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique
US8278428B2 (en) Mitochondrial nucleic acid delivery systems
JP2018520646A (ja) ファブリー病の遺伝子治療
TW201704470A (zh) 變體ＲＮＡｉ
Muraine et al. Transduction efficiency of adeno-associated virus serotypes after local injection in mouse and human skeletal muscle
US20210332368A1 (en) Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
Hoshino et al. The adeno-associated virus rh10 vector is an effective gene transfer system for chronic spinal cord injury
Serguera et al. Gene therapy of the central nervous system: general considerations on viral vectors for gene transfer into the brain
US20230136849A1 (en) Capsid-modified raav vector compositions and methods therefor
JPWO2020160458A5 (fr)
JPWO2020160441A5 (fr)
JPWO2020160468A5 (fr)
Silver et al. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies
JPWO2019173756A5 (fr)
US20240067942A1 (en) Lysosomal acid lipase variants and uses thereof
US20230190893A1 (en) Compositions and methods for treating an inherited retinal disease
WO2023212521A2 (fr) Traitements de troubles de la myéline
WO2022266139A2 (fr) Procédés de modification génétique de cellules souches et progénitrices hématopoïétiques pour l'expression spécifique d'érythrocytes de protéines thérapeutiques
Kojima et al. The adeno-associated virus rh10 vector is an effective gene transfer system for chronic spinal cord injury
Seymour et al. European Society of Gene and Cell Therapy British Society for Gene Therapy Collaborative Congress 2011 October 27–31, 2011 The Brighton Centre, Brighton United Kingdom
Class et al. Patent application title: CAPSID-MODIFIED RAAV VECTOR COMPOSITIONS AND METHODS THEREFOR Inventors: Arun Srivastava (Gainesville, FL, US) Arun Srivastava (Gainesville, FL, US) George V. Aslanidi (Gainesville, FL, US) Sergei Zolotukhin (Gainesville, FL, US) Sergei Zolotukhin (Gainesville, FL, US) Mavis Agbandje-Mckenna (Gainesville, FL, US) Kim M. Van Vliet (Gainesville, FL, US) Li Zhong (Boxborough, MA, US) Lakshmanan Govindasamy (Gainesville, FL, US) Assignees: University of Florida Research Foundation Inc.